Intervention Review

You have free access to this content

Bisphosphonates in multiple myeloma: a network meta-analysis

  1. Rahul Mhaskar1,
  2. Jasmina Redzepovic2,
  3. Keith Wheatley3,
  4. Otavio Augusto Camara Clark4,
  5. Branko Miladinovic1,
  6. Axel Glasmacher5,
  7. Ambuj Kumar1,*,
  8. Benjamin Djulbegovic6

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 16 MAY 2012

Assessed as up-to-date: 15 OCT 2011

DOI: 10.1002/14651858.CD003188.pub3


How to Cite

Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.pub3.

Author Information

  1. 1

    University of South Florida, Center for Evidence Based Medicine and Health Outcomes Research, Tampa, Florida, USA

  2. 2

    Bayer Schering Pharma AG, Berlin, Germany

  3. 3

    University of Birmingham, Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, Birmingham, UK

  4. 4

    Scientific Solutions in Healthcare, EVIDENCIAS, San Paolo, Brazil

  5. 5

    University of Bonn, Bonn, Germany

  6. 6

    Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Professor of Medicine and Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA

*Ambuj Kumar, Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA. akumar1@health.usf.edu. drambujkr@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 16 MAY 2012

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Attal 2006 {published data only}
  • Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108(10):3289-94. [PUBMED: 16873668]
Aviles 2007 {published data only}
  • Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Medical Oncology (Northwood, London, England) 2007;24(2):227-30. [PUBMED: 17848748]
Belch 1991 {published data only}
Berenson 1998a {published data only}
  • Berenson JR, Lichtenstein A, Porter L. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology 1998;16:593-602. [MEDLINE: 115]
  • Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. New England Journal of Medicine 1996;334:488-93.
Brincker 1998 {published data only}
Daragon 1993 {published data only}
  • Daragon A, Humez C, Michot CXLL. Treatment of multiple myeloma with etidronate results of a multicentre double-blind study. European Journal of Medicine 1993;2:449-52. [MEDLINE: 36]
Delmas 1982 {published data only}
  • Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, et al. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metabolic Bone Disease and Related Research 1982;4:163-8. [MEDLINE: 133]
Gimsing 2010 {published data only}
  • Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. The Lancet Oncology 2010;11(10):973-82. [PUBMED: 20863761]
Heim 1995 {published and unpublished data}
  • Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Annals of Hematology 1993;66:141-6.
  • Heim ME, Clemens MR, Queißer W, Pecherstorfer M, Boewer C, Herold M, et al. Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma. Onkologie 1995;18:439-48.
Kraj 2000a {published data only}
  • Kraj M, Póglod R, Pawlikowski J, Maj S, Nasiloska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1: The results of the 12 months of pamidronate therapy. Acta Poloniae Pharmaceutica 2000;57 (suppl 1):113-6.
  • Kraj M, Poglód R, Pawlikowsky J, Maj S. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. Acta Haematologica Polonica 2000;31:379-89.
Lahtinen 1992 {published data only}
Leng 2002 {published data only}
  • Leng Y, Chen SL, Shi HZ. Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma. Hang tian yi xue yu yi xue gong cheng = Space Medicine & Medical Engineering 2002;15(5):377-8. [PUBMED: 12449148]
McCloskey 2001 {published and unpublished data}
Menssen 2002 {published data only}
  • Fontana A, Herrmann Z, Menssen HD, Sakalova A, Boewer C, Facon T, et al. Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma. Blood 1998;92(Suppl 1):106a.
  • Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival and bone resorption in patients with advanced multiple myeloma. Journal of Clinical Oncology 2002;20 (9):2353-9.
Morgan 2010 {published data only}
  • Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376(9757):1989-99. [PUBMED: 21131037]
Musto 2003 {published data only}
  • D'arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leukemia & Lymphoma 2011;1:1-5. [PUBMED: 21299465]
  • Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leukemia & Lymphoma 2003;44(9):1545-8. [PUBMED: 14565658]
Musto 2008 {published data only}
Rosen 2003 {published data only}
  • Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001;91(7):1191-200.
  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98(8):1735-44.
  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer 2001;7(5):377-87.
  • Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
Terpos 2000 {published and unpublished data}
  • Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. European Journal of Haematology 2000;65:331-6.
Terpos 2003 {published data only (unpublished sought but not used)}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Ali 2001 {published data only}
  • Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. Journal of Clinical Oncology 2001;19(14):3434-7.
Barlogie 2008 {published data only}
  • Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112(8):3122-5.
Bergner 2007 {published data only}
  • Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, et al. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. Journal of Clinical Pharmacology 2007;47(8):942-50.
Caparrotti 2003 {published data only}
  • Caparrotti G, Catalano L, Feo C, Vallone R, Pagnini D, Rotoli B. Perspective study on pamidronate in stage I multiple myeloma. The Hematology Journal 2003;4(6):459-60.
Ciepluch 2002 {published data only}
  • Ciepluch H, Baran W, Hellmann A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Medical Science Monitor 2002;8(4):PI31-PI36.
Fizazi 2009 {published data only}
  • Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009;27(10):1564-71. [PUBMED: 19237632]
Kraj 2000b {published data only}
  • Kraj M, Póglod R, Pawlikowski J, Maj S, Nasilowska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Acta Poloniae Pharmaceutica 2000;57(suppl 1):113-6.
Kraj 2002 {published data only}
  • Kraj M, Poglod R, Maj S, Pawlikowski J, Sokolowska U, Szczepanik J. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Poloniae Pharmaceutica 2002;59(6):478-82. [PUBMED: 12669777]
Martin 2002 {published data only}
Morris 2001 {published data only}
Spencer 2008 {published data only}
  • Spencer A, Roberts A, Kennedy N, Ravera C, Cremers S, Bilic S, et al. Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clinical Pharmacology 2008;8:2.
Tassinari 2007 {published data only}
  • Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, et al. Zoledronic acid treatment at home: safety data from an observational prospective trial. Journal of Palliative Medicine 2007;10(2):352-8.
Terpos 2010 {published data only}
  • Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010;24(5):1043-9. [PUBMED: 20376081]
Tosi 2006a {published data only}
Vij 2009 {published data only}
Vogel 2004 {published data only}
  • Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004;9(6):687-95.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Abu-Id 2006
  • Abu-Id MH, Acil Y, Gottschalk J, Kreusch T. Bisphosphonate-associated osteonecrosis of the jaw. Mund Kiefer Gesichtschirurgie 2006;10(2):73-81.
Acito 1994
Agrillo 2006
  • Agrillo A, Petrucci MT, Tedaldi M, Mustazza MC, Marino SM, Gallucci C, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. Craniofacial Surgery 2006;17(6):1080-3.
Alexanian 1994
Aparicio 1998
Atula 2003
  • Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long term use in primary breast cancer patients. Drug Safety 2003;26:661-71.
Badros 2006
  • Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology 2006;24(6):945-52.
Bagan 2006
  • Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]. Oral Oncology 2006;42:327-9.
Battley 2006
  • Battley J, Jayathissa S, Seneviratne E. Jaw osteonecrosis associated with bisphosphonates. The New Zealand Medical Journal 2006;119(1246):U2341.
Begg 1994
Berenson 1998b
  • Berenson JR. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Reviews in Contemporary Pharmacotherapy 1998;9:195-203.
Berenson 2011
Braun 2006
  • Braun E, Iacono VJ. Bisphosphonates: case report of non surgical periodontal therapy and osteochemonecrosis. International Journal of Periodontics and Restorative Dentistry 2006;26(4):315-9.
Broglia 2006
  • Broglia C, Merlati G, Valentino F, Benatti C, Gobbi P, Ascari E, et al. Avascular jaw osteonecrosis associated with bisphosphonate therapy. Recenti Progressi in Medicina (Roma) 2006;97(3):140-4.
Brown 2004
Bucher 1997
  • Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91. [PUBMED: 9250266]
Bujanda 2007
  • Bujanda AD, Sarmiento BU, Suarez CMA, Morales AJ. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Annals of Oncology 2007;18(3):556-60.
Caldwell 2005
  • Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ (Clinical research ed.) 2005;331(7521):897-900. [PUBMED: 16223826]
Calvo-Villas 2006
  • Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J, Carreter de Granda E, Sicilia Guillén F. Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid. Medicina Clinicia (Barcelona) 2006;127(15):576-9.
Capalbo 2006
  • Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, et al. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. International Journal of Hematology 2006;83(5):439-42.
Carneiro 2006
Carter 2005
  • Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Medical Journal of Australia (Sydney) 2005;182:413-5.
Cassidy 2006
  • Cassidy J, Bisset D, Spence RAJ, Payne M, editors. Oxford Handbook of Oncology. New York: Oxford University Press, 2006:504-5.
Cetiner 2009
  • Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Journal of Bone and Mineral Metabolism 2009;27(4):435-43. [PUBMED: 19240969]
Chang 2003
Clarke 2007
  • Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngology--Head and Neck Surgery 2007;136(3):396-400.
Corso 2007
  • Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21(7):1545-8.
Curi 2007
  • Curi MM, Cossolin GS, Koga DH, Araújo SR, Feher O, dos Santos MO, et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. Journal of Oral Maxillofacial Surgery 2007;65(2):349-55.
Dannemann 2007
DerSimonian 1986
Dhodapkar 1998
Dias 2010
Diego 2007
  • Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2007;103(3):e1-5.
Dimitrakopoulos 2006
  • Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. International Journal of Oral and Maxillofacillary Surgery 2006;35(7):588-93.
Dimopoulos 2006
  • Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.
Djulbegovic 2002
  • Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews 2002, Issue 4. [PUBMED: 12137679]
Drake 2008
Dunford 2001
  • Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. The Journal of Pharmacology and Experimental Therapeutics 2001;296(2):235-42. [PUBMED: 11160603]
Durie 2005
  • Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. The New England Journal of Medicine 2005; Vol. 353, issue 1:99-102; discussion 99-102. [PUBMED: 16000365]
Egger M 2001
  • Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition. London: BMJ, 2001.
Elad 2006
Estilo 2004
  • Estilo CS, Van Poznak CH, Williams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study [Abstract]. Proceedings of American Society of Clinical Oncology 2004;22:750.
Ficarra 2005
Fromm 1991
  • Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis International 1991;1:126-33.
Garcia-Garay 2006
  • Garcia-Garay C, Gonzalez-Garcia C, Juliana Majado M, et al. Osteonecrosis of the jaw in multiple myeloma patients: experience of two hospitals. Blood 2006;108(11):Abstract 5086.
Gibbs 2005
  • Gibbs SD, O'Grady J, Seymour JF, Prince HM. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention [Letter]. The Medical Journal of Australia 2005;183:549-50.
Glenny 2005
  • Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. Health Technology Assessment (Winchester, England) 2005;9(26):1-134, iii-iv. [PUBMED: 16014203]
Hansen 2006
Hay 2006
  • Hay KD, Bishop PA. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications. The New Zealand Dental Journal 2006;102(1):4-9.
Herbozo 2007
  • Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery 2007;65(8):1650-4.
Higgins 1996
Higgins 2003
Higgins 2004
Hoff 2006
  • Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. Journal of Clinical Oncology 2006;24:8528a.
Junquera 2009
  • Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. American Journal of Otolaryngology 2009;30(6):390-5. [PUBMED: 19880027]
Jüni 2001
Kademani 2006
Katz 2005
Khamaisi 2006
  • Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. The Journal of Clinical Endocrinology and Metabolism 2007;92(3):1172-5.
Kumar 2007
  • Kumar V, Pass B, Guttenberg SA, Ludlow J, Emery RW, Tyndall DA, et al. Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity. Journal of the American Dental Association 2007;138(5):602-9.
Kut 2004
  • Kut V, Mehta J, Tariman J, et al. Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate. Blood 2004;104:Abstract 4933.
Lambert 2005
Laupacis 1988
Lazarovici 2009
  • Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Journal of Oral and Maxillofacial Surgery 2009;67(4):850-5. [PUBMED: 19304045]
Lenz 2005
  • Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. Jornal of Craniomaxillofacillary Surgery 2005;33:395-403.
Liberati 2009
  • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34. [PUBMED: 19631507]
Lu 2004
  • Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; Vol. 23, issue 20:3105-24. [DOI: 10.1002/sim.1875]
Lufkin 1994
Lugassy 2004
  • Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. American Journal of Medicine 2004;117:440-1.
Magopoulos 2007
  • Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals. American Journal of Otolaryngology 2007;28(3):158-63.
Marunick 2005
  • Marunick M, Miller R, Gordon S. Adverse oral sequelae to bisphosphonate administration. Journal of Michigan Dental Association 2005;87:44-9.
Marx 2003
  • Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery 2003; Vol. 61, issue 9:1115-7. [PUBMED: 12966493]
Marx 2005
  • Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery 2005;63:1567-75.
Mavrokokki 2007
  • Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Journal of Oral and Maxillofacial Surgery 2007;65(3):415-23.
Melo 2005
  • Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. Jornal of the American Dental Association 2005;136(12):1675-81.
Merigo 2006
  • Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Bio-medica: Atenei Parmensis 2006;77(2):109-17.
Mhaskar 2010
  • Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews (Online) 2010, Issue 3. [PUBMED: 20238320]
Migliorati 2005
Montazeri 2007
Mortensen 2007
Murad 2007
  • Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocrine Practice 2007;13(3):232-8.
Pastor-Zuazaga 2006
  • Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez A, Sebastián-López C, et al. Osteonecrosis of the jaws and bisphosphonates: report of three cases. Medicina Oral, Patología Oral y Cirugía Bucal 2006;11:76-9.
Phal 2007
Pires 2005
Polizzotto 2006
Pozzi 2007
  • Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leukemia & Lymphoma 2007;48(1):56-64.
Purcell 2005
Rajkumar 2010
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Ruggiero 2004
  • Ruggiero SL, Meherotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacillary Surgery 2004;62:527-34.
Salanti 2011
  • Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71. [PUBMED: 20688472]
Salesi 2006
  • Salesi N, Pistilli R, Marcelli V, Govoni FA, Bozza F, Bossone G, et al. Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. Anticancer Research 2006;26(4B):3111-5.
Saussez 2009
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
Scurrah 2000
Sedghizadeh 2009
  • Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. Journal of the American Dental Association 2009;140(1):61-6. [PUBMED: 19119168]
Senel 2007
  • Senel FC, Saracoglu Tekin U, Durmus A, Bagis B. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. Journal of Oral and Maxillofacillary Surgery 2007;65(3):562-5.
Shipman 1997
Sitters 2005
  • Sitters MA, Caldwell CS. Bisphosphonates, dental care and osteonecrosis of the jaws. Texas Dental Journal 2005;122:968-72.
STATA V10.1
  • StataCorp LP. STATA. 10.1. College Station: StataCorp LP, 2008.
Sterne 2001
  • Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith S, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition. London: BMJ Books, 2001:189-208.
Tanvetyanon 2006
Thompson 1997
Thompson 2002
Tierney 2007
Tosi 2006b
  • Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006;108(12):3951-2.
Treister 2006
Tricot 2000
  • Tricot G. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ, et al. editor(s). Hematology: Basic Principles and Practice. 3rd Edition. Philadelphia: Churchill Livingstone, 2000.
Van Holten-Verzantvoort 1993
  • Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993;11:491-8.
Vannucchi 2005
  • Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. British Journal of Haematology 2005;28:738.
Walter 2007
  • Walter C, Grőtz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15(2):197-202.
Wells 2009
  • Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons in Meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009:3-22.
Wong 2002
  • Wong RKS, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews 2002, Issue 2. [PUBMED: 12076438]
Wutzl 2006
  • Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wiener Klinische Wochenschrift 2006;118(15-16):473-8.
Yeo 2005
  • Yeo AC, Lye KW, Poon CY. Bisphosphonate-related osteonecrosis of the jaws. Singapore Dental Journal 2005;27:36-40.
Zarychanski 2006
Zervas 2006